CN110100814A - A kind of whole day urine preservative, preparation method and applications - Google Patents
A kind of whole day urine preservative, preparation method and applications Download PDFInfo
- Publication number
- CN110100814A CN110100814A CN201910533804.0A CN201910533804A CN110100814A CN 110100814 A CN110100814 A CN 110100814A CN 201910533804 A CN201910533804 A CN 201910533804A CN 110100814 A CN110100814 A CN 110100814A
- Authority
- CN
- China
- Prior art keywords
- accounts
- urine
- preparation
- preservative
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002700 urine Anatomy 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 239000003755 preservative agent Substances 0.000 title claims abstract description 35
- 230000002335 preservative effect Effects 0.000 title claims abstract description 26
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000843 powder Substances 0.000 claims abstract description 11
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims abstract description 9
- 238000001514 detection method Methods 0.000 claims abstract description 8
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 7
- 229920002472 Starch Polymers 0.000 claims abstract description 7
- 239000011734 sodium Substances 0.000 claims abstract description 7
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 7
- 239000008107 starch Substances 0.000 claims abstract description 7
- 235000019698 starch Nutrition 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 5
- 239000008101 lactose Substances 0.000 claims abstract description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 230000002421 anti-septic effect Effects 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 235000012239 silicon dioxide Nutrition 0.000 claims description 7
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 6
- 229940032147 starch Drugs 0.000 claims description 6
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 4
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 2
- 239000008109 sodium starch glycolate Substances 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 4
- 230000001580 bacterial effect Effects 0.000 abstract description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- 238000005260 corrosion Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229960003511 macrogol Drugs 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 238000009535 clinical urine test Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
Landscapes
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
技术领域technical field
本申请涉及到医疗检测用化学制剂的技术领域,具体的是尿液防腐剂、尿液防腐剂的制备方法及应用。This application relates to the technical field of chemical preparations for medical testing, specifically urine preservatives, preparation methods and applications of urine preservatives.
背景技术Background technique
尿液常规检验是“三大常规”检查项目之一,从其检测结果如红细胞阳性率,白细胞阳性率,尿蛋白水平等可以反映某些早期病症。在肾功能试验中尿液常规检查是极具有临床应用价值的检测项目。由于尿液极易受到细菌污染而影响检测结果的准确性,对临床诊断、治疗等造成极大的影响。因而尿液的防腐对保证尿液检测结果的准确性具有极其重要的意义。目前临床上比较常用的尿液防腐措施是二甲苯和甲苯,其通过隔绝尿液与空气接触达到防腐作用。但是其显著弊端在于在检查中容易混入尿液中一同被取样,同时二甲苯和甲苯属于致癌物质且用量难以控制,对人体有害,不便携带与保存。Routine urine test is one of the "three routine" inspection items, and its test results, such as red blood cell positive rate, white blood cell positive rate, and urine protein level, can reflect some early symptoms. Routine examination of urine is a detection item with great clinical application value in renal function test. Because urine is easily contaminated by bacteria, the accuracy of test results is affected, which has a great impact on clinical diagnosis and treatment. Therefore, the preservation of urine is of great significance to ensure the accuracy of urine test results. At present, the commonly used urine antiseptic measures in clinical practice are xylene and toluene, which achieve antiseptic effect by isolating urine from contact with air. But its obvious disadvantage is that it is easy to be mixed into urine and sampled together during the inspection. At the same time, xylene and toluene are carcinogens and the dosage is difficult to control. They are harmful to the human body and are inconvenient to carry and store.
发明内容Contents of the invention
为解决背景技术中的一个或者多个技术问题,本发明提出了一种全天用尿液防腐剂、尿液防腐剂的制备方法及其应用。In order to solve one or more technical problems in the background technology, the present invention proposes an all-day urine preservative, a preparation method of a urine preservative and its application.
本发明提供一种全天用尿液防腐剂,其组分及对应重量比为:对羟基苯甲酸占比6-34%,乳糖占比47-59.9%,微晶纤维素占比16-29.9%,羧甲淀粉钠占比1.02-3%,硬质酸镁占比0.37-2%,二氧化硅占比0.37-2%。The invention provides an all-day urine preservative, the components and corresponding weight ratios are: p-hydroxybenzoic acid accounts for 6-34%, lactose accounts for 47-59.9%, and microcrystalline cellulose accounts for 16-29.9% %, sodium starch glycolate accounts for 1.02-3%, magnesium stearate accounts for 0.37-2%, and silicon dioxide accounts for 0.37-2%.
或为:对羟基苯甲酸占比6-34%,聚乙二醇6000占比65-88%,羧甲淀粉钠占比1.02-3%,硬质酸镁占比0.37-2%,二氧化硅占比0.37-2%。Or: p-hydroxybenzoic acid accounts for 6-34%, polyethylene glycol 6000 accounts for 65-88%, carboxymethyl starch sodium accounts for 1.02-3%, magnesium stearate accounts for 0.37-2%, dioxide Silicon accounts for 0.37-2%.
与现有技术相比,其有益效果在于:本全天用尿液防腐剂相比传统防腐剂,能够在不破坏原先尿液样本的情况下,抑制尿液样本中细菌的繁殖,维持样本中各项待检测物质的稳定性,避免在24小时后的样本与原来的样本出现变质,进而影响各项检测项目的数据误差,极大提高了尿液防腐剂的防腐性能。Compared with the prior art, the beneficial effect is that: compared with traditional preservatives, this all-day urine preservative can inhibit the reproduction of bacteria in the urine sample without destroying the original urine sample, and maintain the urine sample. The stability of the substances to be tested can avoid the deterioration of the sample after 24 hours and the original sample, which will affect the data error of each test item, and greatly improve the antiseptic performance of the urine preservative.
本发明还提供一种全天用尿液防腐剂的制备方法,其制备步骤如下:The present invention also provides a method for preparing an all-day urine preservative, the preparation steps of which are as follows:
S1、按以下重量比准备相应原料:对羟基苯甲酸占比6-34%、乳糖占比47-59.9%,微晶纤维素占比16-29.9%、羧甲淀粉钠占比1.02-3%、硬质酸镁占比0.37-2%、二氧化硅占比0.37-2%;S1. Prepare corresponding raw materials according to the following weight ratios: p-hydroxybenzoic acid accounts for 6-34%, lactose accounts for 47-59.9%, microcrystalline cellulose accounts for 16-29.9%, and carboxymethyl starch sodium accounts for 1.02-3%. , magnesium stearate accounted for 0.37-2%, silicon dioxide accounted for 0.37-2%;
S2、在常温下,将S1中的组分均匀混合为粉末制剂,或者加压制成片制剂。S2. At room temperature, uniformly mix the components in S1 into a powder preparation, or press to form a tablet preparation.
或为:or as:
S1、按以下重量比准备相应原料:对羟基苯甲酸占比6-34%,聚乙二醇6000占比65-88%、羧甲淀粉钠占比1.02-3%、硬质酸镁占比0.37-2%、二氧化硅占比0.37-2%;S1. Prepare corresponding raw materials according to the following weight ratios: p-hydroxybenzoic acid accounts for 6-34%, polyethylene glycol 6000 accounts for 65-88%, carboxymethyl starch sodium accounts for 1.02-3%, and magnesium stearate accounts for 1.02-3%. 0.37-2%, silicon dioxide accounted for 0.37-2%;
S2、在常温下,将S1中的组分均匀混合为粉末制剂,或者加压制成片制剂。S2. At room temperature, uniformly mix the components in S1 into a powder preparation, or press to form a tablet preparation.
与现有技术相比,其有益效果在于:该制备方法步骤简便,无需剧烈的反应条件,成本低廉,能用于大规模生产,且可以灵活选择制剂的形态。Compared with the prior art, the beneficial effect is that the preparation method has simple and convenient steps, does not require severe reaction conditions, is low in cost, can be used in large-scale production, and can flexibly select the form of the preparation.
本发明还提供一种全天用尿液防腐剂在尿液检测或者存放仪器中的应用。The invention also provides the application of the all-day urine preservative in urine detection or storage instruments.
本发明进一步提供一种全天用尿液防腐剂,制成粉末制剂或者压片制剂。The present invention further provides a urine preservative for all-day use, which is made into a powder preparation or a tablet preparation.
与现有技术相比,其有益效果在于:作为尿液检测中使用的防腐剂,粉末制剂或者片制剂可以适应不同规格和场景的尿液检测器具,在收集到尿液时就可以立刻对尿液样本添加防腐剂,或者提前在集尿器中放置防腐剂,防止在添加防腐剂前尿液样本就产生变质或者被污染。Compared with the prior art, the beneficial effect is that: as a preservative used in urine testing, the powder preparation or tablet preparation can be adapted to urine testing devices of different specifications and scenarios, and the urine can be treated immediately when the urine is collected. Add preservatives to the liquid samples, or place preservatives in the urine collector in advance to prevent the urine samples from deteriorating or being contaminated before adding preservatives.
具体实施方式Detailed ways
为使得本发明技术方案的原理清楚完整,以下列举出部分实施方式的内容,对本申请技术方案做进一步阐述。In order to make the principle of the technical solution of the present invention clear and complete, the content of some implementations is listed below to further elaborate the technical solution of the present application.
全天用尿液防腐剂的具体实施方式,列举6组实施例,各自对应的成分与重量百分比分别如下表1所示,表格里省略数字后面的%。The specific implementation of the urine preservative for all day use includes 6 groups of examples, and the corresponding ingredients and weight percentages are shown in Table 1 below, and the % behind the numbers is omitted in the table.
表1Table 1
相应的,实施例1至6的制备方法,由以下步骤实现:Correspondingly, the preparation method of embodiment 1 to 6 is realized by the following steps:
步骤1、按表格组分和重量比准备相应原料;Step 1, prepare corresponding raw materials according to table components and weight ratio;
步骤2、在常温下,将上述组分均匀混合搅拌为粉末制剂,或者加压制成片制剂。Step 2. At room temperature, uniformly mix and stir the above components to form a powder preparation, or press to form a tablet preparation.
由前述制备方法得到的粉末制剂或者片制剂,应用在尿液检测中。The powder preparation or tablet preparation obtained by the aforementioned preparation method is used in urine detection.
对前述的实施例1至6,在待检测的尿液样本中采用一组未添加防腐剂和一组添加某型进口防腐剂作为对照组,以几项常规的尿液检测项目作为测试结果来说明其防腐效果,具体效果如以下的表2至表4所示:For the foregoing embodiments 1 to 6, a group of no preservatives and a group of imported preservatives were used as control groups in the urine samples to be tested, and several routine urine testing items were used as test results. Illustrate its anticorrosion effect, concrete effect is as shown in following table 2 to table 4:
表2对照组的防腐效果Anticorrosion effect of the control group in table 2
表3实施例1至3的防腐效The preservative effect of table 3 embodiment 1 to 3
表4实施例4至6的防腐效果The anticorrosion effect of table 4 embodiment 4 to 6
从表2至表4的数据可以看出,未防腐组的各项数据均存在波动,特别是亚硝酸盐、细菌计数方面的数据上升明显,出现了大量细菌繁殖的现象。而实施例1至6中添加了本发明的防腐剂后,各项检测数据在24小时甚至48小时后,与一开始的尿液样本相比包括细菌计数的各项成分指标都变化较小,与进口防腐剂组效果相当(尿液形态学未在此次评估指标内)。由此可见,实施例1至6的全天用尿液防腐剂,能够在24小时内一直保持性质稳定,起到长效的杀菌效果,同时也不会影响尿化学项目的检测,实现良好的防腐效果。From the data in Table 2 to Table 4, it can be seen that the data of the non-preserved group fluctuated, especially the data of nitrite and bacteria count increased significantly, and a large number of bacteria reproduced. However, after the preservative of the present invention was added in Examples 1 to 6, each test data compared with the urine sample at the beginning after 24 hours or even 48 hours, and the various component indexes including bacterial counts all changed less, The effect was comparable to that of the imported preservative group (urine morphology was not included in this evaluation index). It can be seen that the all-day urine preservatives of Examples 1 to 6 can maintain stable properties within 24 hours, play a long-term bactericidal effect, and will not affect the detection of urine chemical items at the same time, achieving good antiseptic effect.
进口防腐剂成本昂贵,本发明全天用尿液防腐剂在达到非常好的防腐作用的情况下,同时大大降低成本。Imported preservatives are expensive, and the all-day urine preservative of the present invention can greatly reduce the cost while achieving a very good antiseptic effect.
另外,本发明全天用尿液防腐剂应用十分广泛,还可以用于机场,学校,医院等公用厕所及畜牧业猪牛羊的尿液防腐作用。In addition, the all-day urine preservative of the present invention is widely used, and can also be used in airports, schools, hospitals and other public toilets, as well as the antiseptic function of urine in animal husbandry, pigs, cattle and sheep.
以上实施方式只是本申请技术方案的其中一部分,并非是本发明的全部内容。本领域技术人员应当清楚,任何对上述实施方式的等同替换或者简单增减技术手段,均没有产生实质性特点,依然落入本申请技术方案所限定的范围内。本申请的权利要求保护范围由权利要求书界定。The above embodiments are only a part of the technical solution of the present application, but not the whole content of the present invention. It should be clear to those skilled in the art that any equivalent replacement or simple addition or subtraction of technical means to the above implementations does not produce substantive features, and still falls within the scope defined by the technical solution of the present application. The protection scope of the claims of this application is defined by the claims.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910533804.0A CN110100814A (en) | 2019-06-19 | 2019-06-19 | A kind of whole day urine preservative, preparation method and applications |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910533804.0A CN110100814A (en) | 2019-06-19 | 2019-06-19 | A kind of whole day urine preservative, preparation method and applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110100814A true CN110100814A (en) | 2019-08-09 |
Family
ID=67495621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910533804.0A Pending CN110100814A (en) | 2019-06-19 | 2019-06-19 | A kind of whole day urine preservative, preparation method and applications |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110100814A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05249104A (en) * | 1992-03-05 | 1993-09-28 | Kyoto Ikagaku Kenkyusho:Kk | Preserving method for cell in urine |
| CN1199609A (en) * | 1997-04-30 | 1998-11-25 | 贝克顿迪金森公司 | Additive preparation and method of use thereof |
| CN107560904A (en) * | 2016-07-01 | 2018-01-09 | 山东大学齐鲁医院 | A kind of urine anti-corrosion method for urine chemistries analysis |
-
2019
- 2019-06-19 CN CN201910533804.0A patent/CN110100814A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05249104A (en) * | 1992-03-05 | 1993-09-28 | Kyoto Ikagaku Kenkyusho:Kk | Preserving method for cell in urine |
| CN1199609A (en) * | 1997-04-30 | 1998-11-25 | 贝克顿迪金森公司 | Additive preparation and method of use thereof |
| CN107560904A (en) * | 2016-07-01 | 2018-01-09 | 山东大学齐鲁医院 | A kind of urine anti-corrosion method for urine chemistries analysis |
Non-Patent Citations (4)
| Title |
|---|
| 任晓文 等: "预混辅料直接压片的性质考察", 《现代药物与临床》 * |
| 刘蜀宝 等: "《药剂学》", 31 July 2007, 河南科学技术出版社 * |
| 梁淑娟 等: "羟基苯甲酸酯类防腐剂MIC法临床抑菌效果评价研究", 《海峡药学》 * |
| 段长青 等: "《园艺产品加工学》", 31 March 1997, 世界图书出版公司 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brumfitt et al. | Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers | |
| CN104719671B (en) | A kind of compound essential oil of prevention of diarrhea in piglets and its preparation method and application | |
| CN107988076A (en) | A kind of feces preservation solution and its application | |
| CN104404127B (en) | A kind of strong blood Detection reagent for alanine aminotransferase of stability | |
| Tsuruoka et al. | Adaptation of rabbit cortical collecting duct HCO3-transport to metabolic acidosis in vitro. | |
| CN104762235B (en) | A kind of helicobacter pylori transporting culture medium and its preparation and application | |
| CN104965092A (en) | Preparation method of metal element whole blood control material | |
| CN105560177B (en) | Animal use suspensoid liquid and preparation method thereof containing Amoxicillin and baicalein | |
| Sadeghian et al. | Pasteurella multocida pneumonic infection in goat: Hematological, biochemical, clinical and pathological studies | |
| CN110100814A (en) | A kind of whole day urine preservative, preparation method and applications | |
| Ripa et al. | Concentrations of tinidazole in body fluids and tissues in gynaecological patients | |
| CN103642893B (en) | Neutralizing agent used for detecting microorganisms in cosmetics and preparation method thereof | |
| CN110074099A (en) | A kind of twenty four hours urine preservative, preparation method and applications | |
| CN107557427A (en) | A kind of vibrio parahemolyticus standard substance of the matrix containing the flesh of fish | |
| Hall et al. | The use of dextran sulphate as a blood anticoagulant in biological research | |
| CN110066887A (en) | A kind of virus transporting culture medium and its preparation method | |
| CN102772359A (en) | Enrofloxacin injection and preparation method thereof | |
| CN101921719A (en) | Legionella Transport Enrichment Medium | |
| Friedlander | DNA release as a direct measure of microbial killing by phagocytes | |
| Mitchison et al. | Detection of rifampicin in urine by a simple microbiological assay | |
| Peters et al. | Effect of rifampicin on the kidney of albino rats | |
| Ali et al. | Ovarian hydrobursitis in female camels (Camelus dromedaries): biochemical, bacterial and protozoal evaluation | |
| CN115530155A (en) | 24-hour urine sample preservative, preparation method and application | |
| Lambert et al. | Culture of Vibrio extorquens from severe, chronic skin ulcers in a Puerto Rican woman | |
| Osborn et al. | A comparison of quantitative methods in the investigation of urinary infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190809 |
|
| RJ01 | Rejection of invention patent application after publication |